10-Q quarterly report · filed Nov 10, 2026

Inhibikase Therapeutics, Inc. (IKT) Q3 2026 10-Q Quarterly Report

Short answer

Inhibikase Therapeutics, Inc. (IKT) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$20M
−71.6% YoY · −4.5% QoQ
EPS (diluted)
−$0.10
+28.6% YoY · +9.1% QoQ

Source: XBRL data from the Inhibikase Therapeutics, Inc. (IKT) Q3 2026 10-Q on SEC EDGAR. USD.

Inhibikase Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, no commercial product sales
  • Net loss $20.5M vs $11.9M YoY, operating loss $22.2M vs $12.8M
  • PAH R&D $12.5M vs $5.6M, strongest program, Parkinson’s R&D $0 vs $0.3M
  • Cash, equivalents and marketable securities $193.3M at September 30, 2026
  • Nine-month operating cash use $41.9M vs $20.3M, financing provided $53.3M
  • Outlook: funding expected through topline Phase 3 readout, additional capital likely needed due to ongoing losses

Risk Factors

  • China-related regulation: BIOSECURE Act restrictions could force transition from WuXi AppTec subsidiary STA, delaying IKT-001 supply
  • Most material update: WuXi AppTec added to Section 1260H list in June 2026, with designation challenged and preliminarily enjoined August 7, 2026
  • Compliance risk: proposed restrictions on China-based clinical data could limit trial-site use and increase development costs
  • Operational risk: third-party manufacturing deviations or scale-up failures could delay clinical trials and product launches
  • Supply-chain concentration: STA Pharmaceutical Hong Kong manufactures and supplies IKT-001 drug substance and drug product

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Inhibikase Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.